SolasCure 发布了 Aurase 伤口凝胶的 IIa 期临床试验数据，验证了源自用于伤口愈合的医用蛆的安全性和概念验证。 SolasCure publishes Phase IIa clinical trial data for Aurase Wound Gel, validating safety and proof-of-concept, derived from medical maggots for wound healing.
SolasCure 是一家开发新型伤口护理疗法的生物技术公司，宣布在《国际伤口杂志》上发表其 Aurase 伤口凝胶的 IIa 期临床试验数据，验证其安全性和概念验证。 SolasCure, a biotech company developing novel wound care treatments, announces the publication of Phase IIa clinical trial data for its Aurase Wound Gel in the International Wound Journal, validating its safety and proof-of-concept. 这种水凝胶源自医用蛆，旨在通过清创和伤口床准备来促进伤口愈合。 The hydrogel, derived from medical maggots, aims to promote wound healing through debridement and wound bed preparation. 该出版物标志着 SolasCure 进入进一步临床研究的一个重要里程碑。 The publication marks a significant milestone for SolasCure as it progresses into further clinical studies.